The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RDY | -5.88% | +11.54% | +2.21% | +1,612% |
| S&P | +15.06% | +95.03% | +14.29% | +478% |
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Don't want to pay too steep a price for high-quality stocks? Look abroad.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $998.43M | 8.6% |
| Gross Profit | $535.34M | 1.0% |
| Gross Margin | 53.62% | -4.0% |
| Market Cap | $12.51B | -1.6% |
| Market Cap / Employee | $0.45M | 0.0% |
| Employees | 27.8K | 2.8% |
| Net Income | $164.70M | -1.3% |
| EBITDA | $252.46M | -1.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $104.99M | 78.2% |
| Accounts Receivable | $1.11B | 14.1% |
| Inventory | 881.5 | 7.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $59.42M | -20.5% |
| Short Term Debt | $507.79M | 73.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 12.06% | -2.7% |
| Return On Invested Capital | 15.57% | 0.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $87.16M | 135.5% |
| Operating Free Cash Flow | $167.33M | 70.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 20.68 | 20.50 | 16.45 | 18.79 | -0.90% |
| Price to Book | 3.63 | 3.62 | 2.97 | 3.22 | -14.90% |
| Price to Sales | 3.69 | 3.52 | 2.86 | 3.19 | -12.74% |
| Price to Tangible Book Value | 0.87 | 5.48 | 4.42 | 4.77 | 438.39% |
| Price to Free Cash Flow TTM | 29.05 | 46.21 | 60.03 | 229.82 | - |
| Enterprise Value to EBITDA | 46.65 | 53.49 | 46.13 | 49.02 | -8.40% |
| Free Cash Flow Yield | 3.4% | 2.2% | 1.7% | 0.4% | - |
| Return on Equity | 20.5% | 19.1% | 18.4% | 17.5% | -19.75% |
| Total Debt | $367.86M | $579.23M | $547.15M | $567.21M | 136.30% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
